- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patient Experience with PDTs
Panelists discuss how patients express satisfaction with digital therapeutics for their convenience and real-time accessibility, though lack of payer coverage limits the ability to gather meaningful real-world evidence on their effectiveness.
EP: 1.Discussing Negative Symptoms of Schizophrenia
EP: 2.The Clinical Burden of Negative Symptoms
EP: 3.Exploring the Shortage of Psychiatrists
EP: 4.The Potential of Prescription Drug Therapeutics (PDTs) in Schizophrenia
EP: 5.The Role of PDTs in Clinical Practice
EP: 6.Examining the CONVOKE Clinical Trial
EP: 7.The Future of Pharmacotherapy Plus PDTs
EP: 8.Economic Burden Associated With Schizophrenia
EP: 9.Key Background Information on Prescription Digital Therapeutics
EP: 10.Insurance Coverage of Prescription Digital Therapeutics
EP: 11.Managed Care Considerations for Prescription Digital Therapeutics
EP: 12.The Role of Advanced Practice Providers in Mental Health
EP: 13.Managing Negative Symptoms Associated With Schizophrenia
EP: 14.Current PDTs in Mental Health Disorders
EP: 15.Utilizing PDTs in the Future for Negative Symptoms
EP: 16.Using PDTs in Rural Areas
EP: 17.Combining PDTs With Antipsychotic Medications
EP: 18.Investigational PDTs in Schizophrenia
EP: 19.Patient Experience with PDTs
Patients who have used prescription digital therapeutics (PDTS) report high satisfaction with the convenience and accessibility these tools provide. Many patients appreciate having immediate access to therapeutic interventions when they need them, allowing them to work through difficult emotions and situations in their own space and time. This flexibility is particularly valuable for patients who experience symptoms outside of traditional therapy hours or those waiting months for therapy appointments.
Real-world patient experiences highlight the practical benefits of PDTs, with some patients noting that the cost of digital therapeutics may be comparable to that of therapy co-payments during extended waiting periods for traditional treatment. Patients frequently inquire about apps they discover through social media platforms, demonstrating their interest in digital mental health solutions. However, patients deserve access to evidence-based, FDA-approved digital therapeutics rather than unvalidated alternatives found in app stores.
The lack of comprehensive real-world evidence for PDTs primarily stems from accessibility issues rather than patient satisfaction or effectiveness concerns. Patients cannot provide meaningful feedback about treatments they cannot afford or access due to insurance coverage limitations. When patients do have access to PDTs, their positive experiences and satisfaction demonstrate the potential for these tools to become integral components of mental health care, provided that coverage barriers are addressed to ensure equitable access for all patients who could benefit.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
